Aligos halts ALG-010133 development after Phase 1 data show no meaningful HBsAg reduction

Aligos Therapeutics, Inc.

Halted development of STOPS drug candidate ALG-010133 for chronic hepatitis B.
Phase 1 study showed no meaningful HBsAg reduction at projected efficacious dose of 400 mg.
Higher doses up to 600 mg unlikely to reach 1 log10 IU/mL HBsAg reduction threshold.
No dose-limiting safety findings; decision made jointly with Study Review Committee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.